https://www.selleckchem.com/pr....oducts/sanguinarine-
itivity. These are the first data to provide a quantitative link between prothrombotic viscoelastic coagulation profiles with the development of infection/dehiscence. Based on the cut-points of 33.2 mm MA, 46.6% platelet aggregation, or 55.8% platelet inhibition, we recommend consideration of an enhanced antimicrobial or antithrombotic approach for these high risk groups. 46.6% platelet aggregation, or less then 55.8% platelet inhibition, we recommend consideration of an enhanced antimicrobial or antithrombo